Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Pathol Oncol Res. 2023 May 19;29:1611162. doi: 10.3389/pore.2023.1611162. eCollection 2023.
Immunohistochemistry (IHC)-based protein markers representing molecular subtypes are of great value for routine use. This study aimed to evaluate the frequency distributions of the molecular subtypes of triple-negative breast cancer (TNBC) using IHC-based surrogate markers and examined their prognostic value. Patients with TNBC treated at a university hospital in Southern Thailand were included in this study. Expression levels of androgen receptor, CD8, Forkhead box transcription factor C1, and Doublecortin-like kinase 1 were detected in tumor tissue to classify them into luminal androgen receptor (LAR), immunomodulatory (IM), basal-like immunosuppressed (BLIS), mesenchymal-like (MES), and unclassifiable (UC) subtypes. The association between variables and disease-free survival (DFS) and overall survival (OS) was analyzed using Cox proportional hazards regression. Among the 195 cases of TNBC, the frequency distribution of the IHC-based subtype was as follows: BLIS, 52.8%; LAR, 19.0%; IM, 17.4%; MES, 0.5%; and un-classifiable, 10.3%. BLIS subtype was significantly found in younger ages (mean: 49.6 years) than other subtypes (mean: 51-57.7 years). LAR and BLIS subtypes were significantly associated with poorer OS compared to the IM subtype in univariate analysis, however, only BLIS was significant in multivariate analysis (HR: 3.29, 95% CI: 1.01-10.72). IHC-based subtype was not found to be associated with DFS. This study revealed the differences in the proportion frequency of IHC-based TNBC subtypes in Thai patients compared to other populations. IHC-based molecular subtyping may be beneficial for prognosis. However further refinement of the molecular classification of TNBC is needed for better clinical relevance.
免疫组织化学(IHC)基于蛋白标志物代表分子亚型,对于常规使用具有重要价值。本研究旨在评估使用 IHC 替代标志物的三阴性乳腺癌(TNBC)的分子亚型的频率分布,并研究其预后价值。本研究纳入了在泰国南部一所大学医院治疗的 TNBC 患者。检测肿瘤组织中雄激素受体、CD8、叉头框转录因子 C1 和双皮质激酶 1 的表达水平,将其分为亮氨酸拉链受体(LAR)、免疫调节(IM)、基底样免疫抑制(BLIS)、间质样(MES)和不可分类(UC)亚型。使用 Cox 比例风险回归分析变量与无病生存(DFS)和总生存(OS)之间的关系。在 195 例 TNBC 中,IHC 基于亚型的频率分布如下:BLIS 为 52.8%;LAR 为 19.0%;IM 为 17.4%;MES 为 0.5%;不可分类为 10.3%。BLIS 亚型在年龄较轻(平均年龄:49.6 岁)的患者中明显比其他亚型(平均年龄:51-57.7 岁)更常见。在单因素分析中,LAR 和 BLIS 亚型与 IM 亚型相比,OS 显著较差,但在多因素分析中仅 BLIS 有意义(HR:3.29,95%CI:1.01-10.72)。IHC 基于亚型与 DFS 无关。本研究显示,与其他人群相比,泰国患者的 IHC 基于 TNBC 亚型的比例频率存在差异。IHC 基于分子分型可能对预后有益。然而,为了提高临床相关性,需要对 TNBC 的分子分类进行进一步细化。